Edgar Filing: PRO PHARMACEUTICALS INC - Form 8-K

PRO PHARMACEUTICALS INC

Form 8-K September 24, 2007

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM 8-K _____

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

September 24, 2007 Date of Report (Date of earliest event reported)

PRO-PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter)

NEVADA NEVADA 000-328// 04-3562325 (State or Other Jurisdiction (Commission File Number) (IRS Employer of Incorporation)

000-32877

04-3562325 Identification No.)

7 WELLS AVENUE NEWTON, MASSACHUSETTS

02459 (Address of Principal Executive Offices) (Zip Code)

(617) 559-0033 (Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act I = I(17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 1_1 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the 1_1 Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Change in Directors or Principal Officers, Financial Statements and Exhibits

Item 5.02. Departure of Directors or Principal Officers; Election of Directors:

Edgar Filing: PRO PHARMACEUTICALS INC - Form 8-K

Appointment of Principal Officers.

On September 24, Pro-Pharmaceuticals, Inc. ("the Company") announced that Theodore H. Zucconi, Ph.D., has been named President, a position previously held by David Platt, Ph.D., who will continue to serve as Chief Executive Officer and Chairman of the Board of Directors. Dr. Zucconi also has been nominated to serve on the Company's Board of Directors.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

News Release of Pro-Pharmaceuticals, Inc., dated September 24, 2007.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

PRO-PHARMACEUTICALS, INC.

By: /s/ David Platt

David Platt

Chief Executive Officer

Date: September 24, 2007

EXHIBIT INDEX

Exhibit

Number Exhibit

99.1 News Release of Pro-Pharmaceuticals, Inc., dated September 24, 2007.